Human papillomavirus testing using existing nucleic acid testing platforms to screen women for cervical cancer: implementation studies from five sub-Saharan African countries.
Jessica JosephOwen DemkeLola AmeyanJoseph Bitilinyu-BangoBlandine BourgoinMamadou DiopBabacar GuèyeJibrin KamaMarvin LubegaBernard MadzimaTatenda MaparoTasimba MhizhaAndrew MusokeSusan NabaddaTwambilire PhiriTimothy TchereniOwens WiwaKaren HariharanTrevor PeterShaukat KhanPublished in: BMJ open (2023)
HPV testing was found to be feasible across the five study countries in a public health setting, although attrition was seen at several key points in the cascade of care, namely results return to women and linkage to VIA. Once women received VIA, if eligible, the availability of on-site cryotherapy and thermal ablation allowed for same-day treatment. With sufficient resources and supportive infrastructure to ensure linkage to treatment, use of HPV testing for cervical cancer screening as recommended by WHO is a promising model in low-income and middle-income countries.
Keyphrases
- cervical cancer screening
- public health
- polycystic ovary syndrome
- healthcare
- nucleic acid
- pregnancy outcomes
- primary care
- palliative care
- quality improvement
- mental health
- hiv testing
- breast cancer risk
- men who have sex with men
- chronic pain
- adipose tissue
- human immunodeficiency virus
- affordable care act
- type diabetes
- pain management
- global health